Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 1.00 |
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934124 | 1.00 | HTR2A (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9934591 | 0.89 | DRD2 (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9934593 | 0.89 | DRD2 (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9933412 | 0.87 | HTR2A (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9933414 | 0.87 | HTR2A (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9933999 | 0.86 | DRD2 (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9933997 | 0.86 | DRD2 (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9934877 | 0.81 | HTR2A (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9934874 | 0.81 | HTR2A (1.00) | HTR2ADRD3DRD2 | |
| SCHEMBL9970493 | 0.78 | DRD2 (0.69) | HTR2ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877778-B2 | Benzofurane compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | claimed |
| EP-2651929-A1 | NOVEL BENZOFURANE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | claimed |
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | claimed |
| WO-2012080149-A1 | NOVEL BENZOFURANE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | claimed |
| US-8877778-B2 | Benzofurane compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2651929-A1 | NOVEL BENZOFURANE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012080149-A1 | NOVEL BENZOFURANE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HTR3A, HTR3C, HTR2A | HTR2A 3/4885DRD3 31/4885DRD2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.